Table 3 Baseline characteristics of DM and non-DM patients treated by successful CTO PCI
Study | Age (yrs) DM/Non-DM | Male (%) DM/Non-DM | Smoker(%) DM/Non-DM | HTN (%) DM/Non-DM | LVEF(%) DM/Non-DM | CTO location (%) LAD/LCX/RCA | MVD (%) DM/Non-DM | J-CTO DM/Non-DM | SYNTAX DM/Non-DM |
|---|---|---|---|---|---|---|---|---|---|
Liu et al | 76.58 ± 8.95/ 74.48 ± 8.1 | 66.7/84.5 | 49/67.6 | 78.4/67 | 55.31 ± 16.23/ 57.35 ± 14.5 | NA | 45.1/36.1 | NA | NA |
Sohrabi et al | 58.11 ± 10.94/ 58.23 ± 11.13 | 64.7/80.6 | 20.6/36.4 | 58.8/38 | NA | DM:55.9/17.6/23.1 Non-DM: 61.2/15.5/23.3 | 44.1/34.7 | NA | NA |
Ruiz-Garcia et al | 64.9 ± 9.2/ 63.8 ± 11.0 | 77.3/86.4 | 57.3/54.5 | 70.7/66.7 | 48.4 ± 13.2/ 55.5 ± 12.8 | DM:34.7/0/45.3 Non-DM:44.7/0/36.4 | 65.3/50.8 | NA | NA |
Rha et al | 63.77 ± 9.29/ 64.41 ± 9.88 | 71.6/72.5 | 27.8/27.8 | 76.1/76.0 | NA | DM:40.8/19.9/38.9 Non-DM: 36.7/19.7/43.4 | NA | NA | NA |
Yang et al | 63.02 ± 10.36/ 62.37 ± 11.35 | 74/84 | 38/36 | 77/66 | 51.36 ± 7.46/ 53.00 ± 7.27 | DM:32/15/53 Non-DM: 35/14/51 | 85/76 | NA | NA |
Claessen et al | 62.0 ± 9.8/ 60.5 ± 10.9 | 80.2/85 | 42.8/36.1 | 70.3/62.8 | 52.2 ± 10.2/ 54.5 ± 9.4 | DM:34.6/26.0/39.4 Non-DM: 39.2/18.5/41.8 | 64.5/58.0 | NA | NA |
Tasi et al | 70 ± 12/ 66 ± 14 | 86/96 | 35/46 | 85/68 | 47 ± 12/ 50 ± 12 | DM:40/26/52 Non-DM: 46/26/44 | 85/78 | 2.54 ± 1.00/ 2.31 ± 0.99 | 18 ± 6/ 19 ± 6 |
Guo et al | 64.1 ± 8.9/ 62.9 ± 10.1 | 68.3/79.1 | 34.9/46.7 | 73.5/62.9 | 53.3 ± 9.1/ 54.8 ± 8.1 | DM:40.2/24.5/47.4 Non-DM: 40.5/22.4/48.0 | 77.7/63.5 | 1.41 ± 0.98/ 1.47 ± 1.03 | 21.5 ± 7.5/ 18.9 ± 6.9 |
Sanguineti et al | 65.5 ± 10.4/ 62.2 ± 11.6 | 82.3/86.7 | 21.8/28.6 | 72.8/54.0 | 55.68 ± 9.01/ 57.01 ± 9.57 | DM:31.2/26.4/42.8 Non-DM: 31.1/21.6/47.2 | 64.9/59.4 | 1.45 ± 0.84/ 1.34 ± 0.9 | NA |